Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen